Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
VeinWay Ltd. logo — Changing the paradigm on treating chronic venous disease.

VeinWay Ltd.

Changing the paradigm on treating chronic venous disease.

Founded 2020 Israel Israel 9 employees Series A Health Care, Medical Devices

General Information

Company Name VeinWay Ltd.
Founded Year 2020
Location Israel Israel +1
Employees 9
Industries Health Care, Medical Devices
Funding Stage Series A
Social

Get notified when VeinWay Ltd. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About VeinWay Ltd.

VeinWay Ltd. is a medical device company founded in 2020 by Jordan Pollack within the MEDX Xelerator incubator. The company's slogan "Changing the paradigm on treating chronic venous disease" reflects its mission to address unmet needs in the treatment of Chronic Venous Occlusions (CVOs). VeinWay's Traversa is the first dedicated device designed for venous recanalization, aiming to improve outcomes and enable physicians to reliably, safely, and easily complete endovascular procedures for the effective treatment of CVOs. The innovation has a significantly different approach compared to existing solutions on the market or currently in development, positioning it as a disruptive technology in the Health Care and Medical Devices industries. The company conducted discussions with established physicians from Europe, Israel, and the US, revealing the high unmet need for crossing CVOs in interventional radiology. With failure rates estimated between 10%-17%, and only around 10-13% of patients who need a venous stent actually receive one, VeinWay's Traversa aims to democratize physician access to the treatment of CVOs. The technology provides an unparalleled level of control that will enable interventional radiologists and vascular surgeons to cross occlusions every time, addressing the challenges posed by cumbersome recanalization of chronically occluded veins. The last Series A investment at 08 September 2023 reflects the interest and confidence of investors in VeinWay's innovative solution for the treatment of CVOs. As the company continues to progress, its ability to disrupt the market and improve patient outcomes could make it an attractive prospect for further investment. Based in Israel, VeinWay Ltd. stands at the forefront of addressing critical unmet needs in the field of interventional radiology and vascular surgery with its groundbreaking Traversa technology.

Taxonomy: Medical Device Manufacturing, Interventional Radiology, Vascular Catheters, Venous Vasculature, Chronic Venous Disease, Vascular Surgery, Endovascular Procedures, Medical Technology, Innovation, Recanalization, Physician Access, Thrombotic Syndrome, Innovative Medical Devices, Data-driven Medical Solutions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• - 08 Sep 2023
Non Equity Assistance •••••• 1
Investor
06 Jun 2023
Pre Seed Round •••••• 1 •••• •••• 30 Dec 2021

VeinWay Ltd. Alternatives & Competitors

VeinWay Ltd. vs
enVVeno Medical
enVVeno Medical United States

We are a late clinical-stage medical device company focused on setting new standards of care for Ven...

Post Ipo Equity
28 employees
Manufacturing, Medical Devices
Compare VeinWay Ltd. vs enVVeno Medical
VeinWay Ltd. vs
Lympha Press® Global
Lympha Press® Global Israel

The leader in treatment for lymphedema, lipedema venous insufficiency

51-200 employees
Health Care, Medical Devices
VeinWay Ltd. vs
MESI
MESI Slovenia

We are on the MISSION to simplify diagnostics in primary care and help discover diseases earlier.

Series Unknown
202 employees
AI, Health Care

FAQ About VeinWay Ltd.

Changing the paradigm on treating chronic venous disease.
VeinWay Ltd. was founded in 2020.
VeinWay Ltd. is headquartered in Israel.
VeinWay Ltd. operates in the following industries: Health Care, Medical Devices.
VeinWay Ltd. has approximately 9 employees.
VeinWay Ltd. has completed 3 funding rounds. The latest funding stage is Series A.
Top alternatives and competitors to VeinWay Ltd. include enVVeno Medical, Lympha Press® Global, MESI, CVAM, CardioVascular Associates of Mesa, P.C. , Sonosemi Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VeinWay Ltd. and enVVeno Medical are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors VeinWay Ltd. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes